Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) completed its acquisition of Emalex Biosciences for $700 million, with potential additional ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions